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Abstract
Background—The inverse association between prenatal smoking and preeclampsia is puzzling,
given the increased risks of prematurity and low birthweight associated with both smoking and
preeclampsia. We analyzed the Norwegian Mother and Child Birth Cohort (MoBa) to determine
whether the associations varied by timing of prenatal smoking.
Methods—We conducted an analysis of 74,439 singleton pregnancies with completed second-
and third- trimester questionnaires. Active and passive smoke exposure by trimester were
determined by maternal self-report, and covered the period of preconception through
approximately 30 weeks’ gestation. Adjusted odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated.
Results—Rates of active smoking declined dramatically during pregnancy: for trimester 1, 23%;
trimester 2, 9%; and trimester 3, 8%. Active smoking in the third trimester was associated with
reduced odds of preeclampsia and gestational hypertension, with the strongest association among
continuous smokers (for preeclampsia, OR = 0.57 [95% CI = 0.46–0.70]). Women who quit
smoking before the third trimester had approximately the same risk of preeclampsia and
gestational hypertension as nonsmokers. There was some evidence of dose-response, with the
heaviest smokers (more than eight cigarettes per day) having the lowest risks of preeclampsia
(0.48 [0.32–0.73]) and gestational hypertension (0.51 [0.28–0.95]). There was little evidence of an
association with passive smoking exposure.
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Conclusion—The association between smoking and preeclampsia varies substantially according
to the timing and intensity of exposure. A better understanding of the biologic pathways that
underlie these associations may provide important clues to the etiology of preeclampsia and the
development of effective clinical interventions.
The reduced risk of preeclampsia with maternal smoking during pregnancy is inconsistent
with the many well-documented harmful effects of smoking, including increased risk of
stillbirth and infant mortality.1,2 The reduction in risk with maternal smoking is estimated to
be 30%–50%.3–5 However, arriving at a clear biologic mechanism to explain these findings
has been complicated by the observation that maternal active smoking is also strongly
associated with decrements in birthweight6–8 and modest increases in risk for preterm
delivery,9,10 both of which also result from preeclampsia and should thus be decreased if
preeclampsia is prevented by smoking.
Preeclampsia is not the only condition thought to be prevented by active smoking. Parkinson
disease is another.11 It is possible that some therapeutic intervention could evolve from a
better understanding of the biological mechanism of such protective effects. Even though the
net harm from smoking remains unarguable, understanding how an exogenous, modifiable
factor affects preeclampsia risk could also shed light on the etiology of preeclampsia.
Despite the robust literature examining the influence of passive/environmental smoke
exposure on birthweight or prematurity, to our knowledge there have been no studies on the
influence of passive smoke exposure on preeclampsia or gestational hypertension.
Additionally, there is very limited literature on trimester-specific effects of active smoking
on hypertensive disorders of pregnancy, with one recent study based in the Swedish Medical
Birth Registry finding that reduced risk of preeclampsia was limited to women who
continued smoking into their late pregnancy.5
We undertook a prospective investigation of the trimester-specific effects of active and
passive smoking on preeclampsia and gestational hypertension in the Norwegian Mother and
Child cohort (MoBa), a population-based cohort recruited between 1999 and 2008,
comprising about 18% of all deliveries in Norway during the study period.12
METHODS
Study Population and Design
The Norwegian Mother and Child cohort (MoBa) enrolled over 100,000 women between
1999 and 2008. Study design and selection characteristics have been described in detail
elsewhere.12,13 Briefly, women were invited to participate by mail prior to their routine
ultrasound examination at their local hospital, which generally occurs around 18 weeks’
gestation. Women consenting to participate completed two self-administered exposure
questionnaires during their pregnancy. The first maternal and paternal questionnaires (Q1)
were sent by mail with the consent form prior to the ultrasound appointment (95%
completed). The mean gestational age at which the first questionnaire was completed was
17.6 weeks (standard deviation = 2.8). A second questionnaire covering maternal health
status and habits since the first questionnaire was mailed to participants at approximately
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week 30 (Q3) (92% completed, mean gestational age 30.7 [1.6] weeks). In some cases
(0.4%), the last questionnaire was received following delivery. Women were allowed to
participate for more than one pregnancy within the study period (15% with repeat
pregnancies). Participation rate varied by study year,12 but averaged 39%. The final MoBa
population comprised approximately 18% of all deliveries in Norway during the study
period. There were no differences between the enrolled MoBa population and the entire
population with respect to prevalence of preeclampsia and chronic hypertension, although
active smokers were under-represented among the MoBa participants (11% vs. 6%).12
Pregnancy Smoking Information
Women were queried twice during pregnancy regarding their personal smoking habits and
their exposure to passive/environmental tobacco smoke at work or home. In the first
questionnaire (~18 weeks’ gestation), mothers were asked whether they currently smoked (if
so, how many cigarettes per day/week), or if they had stopped smoking after they became
pregnant, and if so, at what gestational age. If a woman reported quitting smoking after she
became pregnant but did not report the amount she smoked up until she quit (n = 10,073),
we used the amount she reported in the 3 months before she became pregnant. If that was
unavailable (n = 417), she was considered to be a smoker until the gestational week she
reported quitting, but with a missing dose for that period. If a woman reported quitting but
did not provide the gestational age at which she quit (n = 148), we assumed she quit at the
midpoint of her current trimester. If a woman reported smoking during pregnancy, but did
not report whether or not she quit (n = 5,852), we assumed she continued smoking. We used
the dose information provided in the first questionnaire to cover the first- and second-
trimester exposure, or up until a specified quit week. In the next questionnaire (~32 weeks’
gestation), women were asked whether they currently smoked and how much, and, if they
had quit at some point during pregnancy, at what gestational age. We used the dose
information provided in this questionnaire to cover the third trimester until delivery, or until
a specified quit week. Dose information was categorized into four groups: “None” and then
ter-tiles rounded to the nearest whole cigarette above (>0 to <2, 2 to <8, ≥8 cigarettes per
day). In both questionnaires, passive smoke exposure at work and home was reported, along
with the number of hours exposed per day.
Birth Outcome Information
Birth outcome information was obtained by linkage with the Medical Birth Registry of
Norway. The registry receives delivery information from hospitals using a standardized birth
notification form.14 This form provides demographic information on the mother and father,
mother’s health before and during pregnancy including chronic diseases and pregnancy
complications, as well as infant birth defects and delivery characteristics. A designation of
gestational hypertension alone, or preeclampsia/eclampsia, is completed by a hospital
midwife using information from the mother’s antenatal medical record and additional data
recorded at the maternity department upon admission. Preliminary analyses of the positive
predictive value of preeclampsia registrations as compared with blood pressure and protein
measures on personal antenatal records and hospital discharge codes indicate that the
preeclampsia registrations have strong validity (Klungsøyr K, unpublished data).
Information on maternal chronic hypertension and diabetes is also contained in the registry.
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Preeclampsia and gestational hypertension were considered separately in the analysis.
Women with preexisting/chronic hypertension, including preeclampsia superimposed on
chronic hypertension, were excluded from all analyses (n = 372). Overall, the risk of
preeclampsia in this population was 3.5% (n = 2,564) and the risk of gestational
hypertension was 1.9% (n = 1,935).
Statistical Analysis
MoBa data were from the version 4 release of quality-assured data. Of the 90,190 MoBa
pregnancies in which Q1 was completed, 77,041 also had Q3 completed, of which 74,439
were singletons. Additionally, women who delivered prior to the onset of their third
trimester (gestational age at delivery <27 weeks) were excluded (n = 2,378). There were
8,209 women who contributed two or more pregnancies to this analysis (7,890 with two
pregnancies, 311 with three pregnancies, and eight with four pregnancies).
The following covariates were considered as potential confounders or effect modifiers:
maternal age (linear and quadratic term), prepregnancy body mass index, parity, marital
status, maternal education, educational disparity between mother and father, household
income, and any diabetes prior to or during pregnancy. We constructed directed acyclic
graphs to explore the possible relations between active and passive smoking, the above
covariates, and preeclampsia or gestational hypertension. We adjusted for covariates
indicated by an inspection of directed acyclic graphs, although we also included highly
predictive covariates that improved the overall precision of the model. We evaluated the
final model for parsimony after inspecting changes in the main effect estimate. Women who
were missing active or passive smoking exposure information were dropped from the
models. For the main analysis of active and passive smoking in relation to preeclampsia and
gestational hypertension, multiple imputation (five replications) was used to impute missing
values for body mass index (BMI) and education. Specifically, in SAS, we first used the
Markov Chain Monte Carlo method to construct five data sets, just enough missing values to
have a monotone missing value, and then used the discriminant function on each of these
data sets to impute education. The imputed continuous values for BMI were placed in
discrete categories. We evaluated the interaction between smoking and maternal BMI,
smoking and maternal age, and smoking and parity, including any interactions in the model
if the P value for the product term was less than 0.10. Multivariable logistic regression using
Proc Genmod was implemented in SAS 9.2 (Cary, NC), using the repeated statement to
account for multiple observations per woman.
RESULTS
There were 74,067 singleton pregnancies with complete pregnancy questionnaire data
(Table 1). Among these, 17,014 (23%) reported active smoking at some point during
pregnancy. Among women who reported any smoking during pregnancy, 47% reported
quitting in the first trimester, 6% reported quitting in the second trimester, and 1% reported
quitting in the third trimester. In general, smokers tended to be younger, primiparous, less
educated, more likely to be single at the time of pregnancy, and have smaller personal
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incomes. Smokers were also much more likely to report passive smoke exposure at home or
work.
Rates of smoking declined dramatically during pregnancy. Approximately 23% of women
reported active smoking in trimester 1, which declined to 9% in trimester 2 and 8% in
trimester 3. Patterns of smoking behavior and their associated risks for preeclampsia and
gestational hypertension are described in Table 2. Women who quit smoking prior to the
onset of their third trimester had roughly the same risk of preeclampsia and gestational
hypertension as non-smokers. In general, smoking during the third trimester was required to
produce a substantial decrement in risk of disease. Because few third-trimester smokers take
up the habit in the third trimester, we cannot separate the effect of continuous exposure from
exposure during the third trimester alone. For both preeclampsia and gestational
hypertension, women with continuous exposure throughout pregnancy had the strongest
reduction in risk of disease (Table 2).
We estimated the associations of trimester 1, trimester 2, and trimester 3 active and passive
smoking with preeclampsia and gestational hypertension (Table 3). In models considering
each trimester separately (model 1), active smoking only (ever vs. never) was associated
with lower odds of preeclampsia in all trimesters, with the strongest associations in
trimesters 2 and 3. Passive smoke exposure alone was also associated with minor
decrements in risk across pregnancy. Although consistent in direction with active smoking,
the passive smoking estimates were weak. Active and passive smoke exposure together was
also associated with reduced odds of preeclampsia in every trimester—again most strongly
in trimesters 2 and 3. Women who smoked throughout the pregnancy also tended to smoke
more heavily (40% of women who quit smoking before their second trimester reported
smoking less than 1 cigarette per day, whereas only 13% of women who smoked throughout
pregnancy reported smoking so little in the first trimester). We conducted a sensitivity
analysis in an attempt to isolate the effect of timing from that of dose in early pregnancy.
We reran the third-trimester model 1 (Table 3), including the additional adjustment variable
of dose in trimester 1, and found no appreciable change in the estimate of relative risk or the
precision of the overall association. This suggests that there is some independent effect of
exposure timing on the overall association of smoking with preeclampsia.
To shed additional light on the association with exposure in trimester 3, we performed
additional analyses (model 2) that adjusts the trimester 3 association for smoking in
trimester 2. (We limited ourselves to adjusting trimester 3 results because, in general,
smoking status in trimesters 1 and 2 were correlated in the sense that exposure history was
ascertained during the same interview, and there were no nonsmokers at trimester 1 who
reported starting smoking at trimester 2.) The analysis suggests that adjusting for prior
trimesters did not substantially change the trimester 3 effects, although the association
became much less precise (eg, for the association of active smoking with preeclampsia, odds
ratio [OR] = 0.56 unadjusted for prior history vs. 0.63 adjusting for trimester 2 smoking,
which is a 13% change in OR).
A similar pattern was found for gestational hypertension (approximately 11% change in
estimated effect) (Table 3). We found no evidence of effect modification of these
Engel et al. Page 5






















associations by parity, maternal age, or body mass index. Moreover, results were unchanged
when adjusted for the length of the third trimester (in order to account for the possibility that
smokers delivered prior to development symptoms of preeclampsia). Overall, active
smoking in trimester 2 and trimester 3 appeared to be associated with the strongest
reductions in risk for both preeclampsia and gestational hypertension.
We used multiple imputation to account for missing data on key covariates in Table 3. When
observations with missing data for key covariates were instead excluded, in general, the
point estimates and confidence limits of the smoking effects were consistent to the second
decimal place (data not shown).
For both preeclampsia and gestational hypertension, odds of disease dropped markedly from
the lightest to the heaviest smokers (Table 4). However, overall there were few “light”
smokers during this period, and a substantial number reporting no daily cigarette usage.
DISCUSSION
In this population-based study of Norwegians, we observed a strong reduction in risk of
preeclampsia and, to a lesser degree, gestational hypertension, among women who reported
smoking in their third trimester of pregnancy. Moreover, the associations were stronger
among women who reported heavier smoking in this period, both for preeclampsia and for
gestational hypertension. It is notable that women who quit smoking prior to the onset of
their third trimester experienced roughly the same risk of preeclampsia as nonsmokers. This
is somewhat inconsistent with a recent study indicating that women who smoke in the first
trimester have a steeper increase in mean systolic blood pressure throughout pregnancy, and
a steeper increase in mean diastolic blood pressure in later pregnancy, compared with
nonsmokers.15 However, their study was much smaller than ours, with only 49 exposed
gestational hypertension cases and 20 exposed preeclampsia cases.
Trimester-specific associations with smoking have not been widely studied. In a small
hospital-based case-control study, Xiong et al16 found smoking in pregnancy to be inversely
related to risk, but there were too few exposed cases to distinguish early versus late effects.
Marcoux et al,17 also in a hospital-based case-control study, reported that smoking cessation
prior to 20 weeks’ gestation resulted in an attenuation of the apparent protection provided by
maternal smoking. England et al18 analyzed smoking data collected from a randomized
clinical trial, and found that prepregnancy smoking was not protective, while smoking at the
enrollment visit (which occurred at some point between 13 and 21 weeks) was. Very similar
results were found by Zhang and colleagues,19 in historical data from the Collaborative
Perinatal Project (CPP) (smoking information collected at ~18 weeks), and also by Sibai et
al20 in an analysis of a randomized clinical trial with personal smoking history:
prepregnancy smoking was not associated with reduced risk, but current smoking at
enrollment was. However, none of these studies was able to describe smoking patterns
continuously across trimesters. It is also likely that in each of these studies, except perhaps
the CPP, a large proportion of first-trimester smokers were misclassified because the largest
drop in smoking rates occurred between the second and third trimesters. Few women appear
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to quit smoking later in pregnancy, making it difficult to disentangle second and third
trimester-specific effects.
Wikström and colleagues5 recently reported results from the Swedish Birth Register, using
all singleton births in Sweden during the years 1999–2006. Information on smoking and
snuff use was collected at two time points: at the first antenatal visit (approximately 15
weeks’ gestation) and at approximately week 30–32. Information on first-trimester smoking
was not available (eg, if a woman was not a current smoker at 15 weeks). Wikström et al5
analyzed smoking in discrete categories: smoking or smokeless tobacco use at the first
interview and smoking or smokeless tobacco use at the second interview. In that study,
continuous smokers and smokers at the second interview had the greatest reduction in risk,
both for preeclampsia and gestational hypertension, with no reduced risk associated with
snuff use (suggesting that the causal agent is not nicotine, but rather some product of
combustion).
It remains plausible that residual or unmeasured confounding partly explains the consistently
inverse associations of prenatal smoking with preeclampsia. One possible pathway is that
genetic traits associated with addiction to smoking are also directly associated with
preeclampsia through another unblocked pathway. A similar concern has arisen in the
literature linking prenatal smoking with childhood attention deficit hyperactivity disorder
(ADHD). Although maternal prenatal smoking has been consistently associated with
increased risks of ADHD in offspring in a number of human21,22 and animal23,24 studies, the
use of a sib-pair design to control for unmeasured confounding reduced the magnitude of the
association dramatically.25 Likewise, the CPP (conducted when smoking was far more
prevalent during pregnancy) found no association between maternal smoking and ADHD.26
However, a protective and dose-response association between antenatal smoking and
preeclampsia was reported in the CPP,19 dispelling some of the concerns that residual
confounding might entirely explain the association of smoking with preeclampsia.
Preeclampsia studies using designs that are more robust to genetic or other unmeasured
confounders, such as the sib-pair design, should be explored, but may be challenging to
implement given the strong association between parity and preeclampsia.
Preeclampsia is considered a two-stage disease.27 The first stage is caused by abnormal
placentation due to insufficient invasion of extravillous cytotrophoblasts, leading to
insufficient remodeling of the maternal spiral arteries and a reduced placental perfusion.28,29
The second stage of preeclampsia (the maternal systemic disorder) is likely to develop as a
consequence of placental ischemia. Because sufficient uteroplacental blood flow is a key
element in successful implantation and reproductive outcome, increased attention has been
devoted to altered angiogenesis in preeclampsia. Recent research has focused on angiogenic
factors and their role in the development of preeclampsia. Placental ischemia is believed to
release endothelial damaging factors to the maternal circulation,27 and antiangiogenic
factors are likely to play a role in the development of preeclampsia. Decreased
concentrations of circulating angiogenic factors, free placental growth factor and free
vascular endothelial growth factor, have been reported in preeclamptic pregnancies,30 as
have increased concentrations of the antiangiogenic factors soluble fms-like tyrosine kinase
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1 (sFlt-1) (which is an inhibitor of placental growth factor and vascular endothelial growth
factor) and soluble endoglin (sENG).31,32
The inverse association between smoking during pregnancy and risk of preeclampsia could
be causal. Various biologic mechanisms have been proposed to explain this association,
including carbon monoxide–mediated inhibition of inflammation,33 enhanced
vasodilation,34 and suppression of platelet aggregation,35 plasminogen activation,35
apoptosis,36,37 reactive oxygen species formation38, and sFlt-1, an antiangiogenic
factor.39,40 Altered function of sFlt-1 has been associated with well-established risk factors
for preeclampsia. Primiparity and twin pregnancy are major risk factors, separately2 and
together.41 Wolf et al42 reported a decrease in circulating sFlt-1 from first to second
pregnancy, suggesting that higher levels of sFlt-1 may predispose to preeclampsia. Higher
levels of sFlt-1 have also been found in twin pregnancies,43 and lower sFlt-1 levels have
been found in pregnancies of smokers,44 further supporting this hypothesis. A recent nested
case-control study demonstrated higher gestational age–specific birthweights and lower
sFlt-1 levels in smokers with preeclampsia as compared with nonsmokers with
preeclampsia.45 The authors suggest smoking may exert this effect by reducing levels of
sFlt-1.
Heterogeneity in associations of smoking with preeclampsia risk according to trimester of
exposure may provide some clues as to the underlying mechanism. Clinical preeclampsia
usually emerges after the middle of the second trimester, coincident with substantial rises in
sFlt-1 and sENG, and may explain why smoking during the latter half of the pregnancy as
demonstrated in our study and others seems more beneficial.46
There is likely to be some misclassification of outcome in our study (eg, gestational
hypertension labeled preeclampsia or the reverse). In general, the patterns of association for
these outcomes were similar, and thus it is difficult to argue that the smoking effect is
specific to preeclampsia, although the magnitude of associations was stronger for this
outcome. Differential recall of smoking behavior is made less likely by the prospective
design of exposure ascertainment, with the first-trimester smoking behaviors reported prior
to 20 weeks’ gestation. Smoking behaviors during late pregnancy may have been reported
coincident with the symptoms or diagnosis of disease. Biomarkers of smoking exposure
(such as cotinine levels)—unless they were collected at multiple times during pregnancy—
would be unlikely to substantially improve estimates of exposure, given the significant
variability in smoking patterns across pregnancy in this population and others.47
Additionally, the analytic approach would be improved by time-to-event modeling, in which
competing risks for delivery (eg, prematurity) could be explicitly accounted for.
Unfortunately, this approach requires the availability of gestational age at onset of
symptoms, which is rarely available.
In conclusion, our results add to the weight of evidence implicating smoking exposure
during late pregnancy as the critical determinant of the inverse association between antenatal
smoking and preeclampsia. Although the pathways underlying the association remain
unknown, eventual elucidation may help to identify treatment options for this dangerous and
enigmatic disorder.
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TABLE 1
Participant Characteristics According to Maternal
Active Smoker (n = 17,014) Nonsmoker (n = 57,053)
No. (%) No. (%)
Age (years)
 ≥20 790 (4.6) 645 (1.1)
 21–30 9,689 (57.0) 28,475 (49.9)
 31–40 6,401 (37.6) 27,280 (47.8)
 ≥41 134 (0.8) 653 (1.1)
BMI (kg/m2)a
 <18.5 644 (3.9) 1,527 (2.8)
 18.5–25 10,063 (61.1) 37,058 (66.7)
 26–30 3,848 (23.4) 12,027 (22.6)
 ≥30 1,911 (11.6) 4,988 (9.0)
Parity
 0 8,789 (51.7) 25,430 (44.6)
 1 5,427 (31.9) 20,996 (36.8)
 ≥2 2,798 (16.4) 10,627 (18.6)
Marital statusb
 Married/cohabitating 15,747 (93.2) 55,622 (97.9)
 Single/divorced/widowed/separated 863 (5.1) 785 (1.4)
 Other 292 (1.7) 414 (0.7)
Educationc
 <High school 6,082 (37.9) 9,172 (16.9)
 High school 3,286 (20.5) 7,463 (13.8)
 >High school 6,661 (41.6) 37,576 (69.3)
Past year personal income
 <200 NOK 7,456 (43.8) 17,618 (30.9)
 200–299 NOK 5,782 (34.0) 20,430 (35.8)
 ≥300 NOK 3,776 (22.2) 19,005 (33.3)
Passive smoke exposured 2,841 (16.9) 2,400 (4.2)
Preeclampsia 604 (3.6) 1,960 (3.4)
Gestational hypertension 299 (1.8) 1,096 (1.9)
NOK, Norwegian currency (Krone).
a
2,001 women were missing information on BMI.
b
344 women were missing information on marital status.
c
3827 women were missing information on education.
d
397 women were missing information on passive smoke exposure.
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